Business Wire

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer

4.11.2026 14:41:00 CET | Business Wire | Press Release

Share

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/

Andrew Glass, CEO, TTxD

Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary RIDE platform technology. This includes expanding its immunology and inflammation program, including the nomination of the clinical candidate for RIDE-002 and ongoing management of its stakeholder relationships to secure options for future growth.

Stefano Buono, Chairman of the Board of TTxD, said:

"On behalf of the Board, I am very pleased to welcome Andrew to the Company at a pivotal moment in its development when his track record of building and scaling innovative life sciences will be invaluable. He leads an exceptional team of people at TTxD, supported by our founding shareholders, who are focussed on realizing the full potential of the RIDE platform."

Andrew Glass, Chief Executive Officer of TTxD, said:

"I am delighted to join Trained Therapeutix Discovery at an important inflection point after a decade of development and investment. The Company’s RIDE platform offers a fundamentally new way to treat immune-mediated disease, by reprogramming innate immunity where it begins. Turning strong science into effective products that reach patients is where my skills complement the many people within TTxD who are leading development in this breakthrough area of science."

TTxD's RIDE platform is designed to target myeloid progenitor cells that shape how our innate immune system behaves. By reprogramming innate immunity at its origin, the platform aims to achieve more precise and durable control of immune responses. RIDE-002 is being developed for inflammatory diseases including but not limited to hidradenitis suppurativa and inflammatory bowel disease.

About Andrew Glass

Andrew Glass is an experienced life sciences executive with a track record of aligning research and development with commercial goals to grow innovative technologies. Since 2021 he has served as Chief Executive Officer of Vivasure Medical, a Ireland-based company developing fully absorbable solutions for large-bore percutaneous vessel closure. Under his leadership, Vivasure product PerQseal achieved European commercialization, obtained US FDA IDE approval and submitted a premarket approval application to the FDA. In January 2026 the Company was sold to Haemonetics Corporation for total of $215 Million.

Before Vivasure, Andrew spent 15 years in senior leadership roles at Abbott, most recently as Regional Director at Abbott Vascular, responsible for commercial operations across 13 European countries. Earlier, he held senior positions in general management, business development and marketing in Europe, Asia-Pacific and the United States. Andrew holds a Harvard MBA and degree in Chemical Engineering and Molecular Biology from Princeton.

About Trained Therapeutix Discovery

Trained Therapeutix Discovery is a biotechnology company developing a nanomedicine platform designed to modulate the innate immune system at its origin. The company's RIDE platform targets myeloid progenitor cells with the aim of addressing immune dysregulation in conditions such as inflammatory diseases and cancer. The company's lead programs are RIDE-001 in oncology and RIDE-002 in immunology and inflammation. Trained Therapeutix Discovery was founded by the Jean Boulle Group and the Heritage Group, long-term investors with experience in building and scaling innovative science and technology ventures. For more information, visit ttxdiscovery.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104178009/en/

Contacts

For Trained Therapeutix Discovery investor relations & business development:
investor@ttxdiscovery.com

For press & media enquiries:
Michael Oke/Khushi Hunt
boulle@aura-financial.com
+44 020 7321 0000

To learn more about Trained Therapeutix Discovery, our RIDE platform, and
ongoing advancements, visit www.ttxdiscovery.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fconnect.notifi
ed.com%2FTracker%3Fdata%3DrOzjF0XJTEac813jUZI1gT7bGFsRxjslJ180zgTBB4bQwL0nOzWCkm
XbAVFVPg94Cc2d7GcNTT2abZveaAH3OqY5GVJTHb1EHaVSwrtWJQQ%3D000210151469&esheet=5463
5167&newsitemid=20261104178009&lan=en-US&anchor=www.ttxdiscovery.com&index=2&md5
=8e790b40b5a3a976a396df059963f660

For more about the Jean Boulle Group: www.jeanboullegroup.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fconnect.notifi
ed.com%2FTracker%3Fdata%3D4dL9zjEWsaSVtqlDXxLT680ml47nctaOjakGT1ZoG8z01QsigUEnxn
h4gGyiDIhuD5_PpKkli8AY3ouqejnzyL0kMs9htTRlTGVJyC2kogH0uB_ZwX35j3NE7vCeAyyM000210
151469&esheet=54635167&newsitemid=20261104178009&lan=en-US&anchor=www.jeanboulle
group.com&index=3&md5=1f5ce11289cf342c0ddd0cdfb820c7c5

For more about the Heritage Group: www.heritagemonaco.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fconnect.notifi
ed.com%2FTracker%3Fdata%3DFANR1kWjTw4PKoNmxrL4t_6DcQY16Qi7HgT7Uf_N8derf9GHWnPE4t
qw8Gv3L8rj-swoQkEutg1Z0EpY6YZavBGLBXemd9UOuGbq11kjGkRCkz512oM22cRo99Q4uiwe000210
151469&esheet=54635167&newsitemid=20261104178009&lan=en-US&anchor=www.heritagemo
naco.com&index=4&md5=eaf4188c34e8e90ce3e7ec590de66388

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 02:30:00 CET | Press Release

Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for the first time reflects both the strength of India's technology ecosystem and the growing role its enterprises play in shaping global supply chai

Povofortay ® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 22:30:00 CET | Press Release

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on results from the pivotal STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836) trials evaluating the safety and efficacy of Povofortay in patients with moderate to severe HS.2 Data from the Phase 3 STOP-HS program demonstrated Povofortay’s clinically meaningful and

Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 22:00:00 CET | Press Release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platform is well suited to a terminal that must run for years without maintenance. “As optical links and onboard processing

Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 22:00:00 CET | Press Release

Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise workflows and move AI agents from pilots into everyday work. Mr. Bhatt will also continue as Chief Technology Officer of Moody’s Ratin

New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 18:00:00 CET | Press Release

Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an audience of over 300 million players, the survey shows an engaged audience with established spending habits: 84% of respondents call themselves gam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye